Bahrt Kenneth 4
4 · Oncobiologics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
Bahrt Kenneth
Chief Medical Officer
Transactions
- Sale
Common Stock
2018-06-25$0.85/sh−7,700$6,507→ 47,120 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.845 to $0.8525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]Includes 14,493 shares of the Issuer's common stock subject to RSUs that will vest on 6/22/19, the four-year anniversary of the 6/22/15 grant date, subject to continued service through such date.